Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.33 Average PT from Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been given a consensus rating of “Moderate Buy” by the five analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.3333.

Several brokerages have recently commented on AUTL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Needham & Company LLC reduced their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Monday. Wall Street Zen downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Finally, William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th.

Autolus Therapeutics Stock Performance

Shares of AUTL stock opened at $1.44 on Tuesday. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $2.70. The company’s 50 day moving average price is $1.56 and its two-hundred day moving average price is $1.75. The company has a market capitalization of $383.24 million, a P/E ratio of -1.73 and a beta of 2.01.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.07). The firm had revenue of $21.19 million for the quarter, compared to analyst estimates of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. Analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. increased its holdings in Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after buying an additional 11,381 shares during the period. Jane Street Group LLC boosted its position in shares of Autolus Therapeutics by 809.4% during the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock worth $159,000 after acquiring an additional 91,222 shares in the last quarter. Atle Fund Management AB boosted its position in shares of Autolus Therapeutics by 130.5% during the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock worth $2,520,000 after acquiring an additional 625,817 shares in the last quarter. Avanza Fonder AB increased its stake in Autolus Therapeutics by 151.6% in the second quarter. Avanza Fonder AB now owns 53,522 shares of the company’s stock valued at $122,000 after acquiring an additional 32,246 shares during the last quarter. Finally, Forefront Wealth Management Inc. acquired a new position in Autolus Therapeutics during the second quarter valued at approximately $61,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.